Highly efficient therapeutic gene editing of human hematopoietic stem cells
Yuxuan Wu,Jing Zeng,Benjamin P Roscoe,Pengpeng Liu,Qiuming Yao,Cicera R Lazzarotto,Kendell Clement,Mitchel A Cole,Kevin Luk,Cristina Baricordi,Anne H Shen,Chunyan Ren,Erica B Esrick,John P Manis,David M Dorfman,David A Williams,Alessandra Biffi,Carlo Brugnara,Luca Biasco,Christian Brendel,Luca Pinello,Shengdar Q Tsai,Scot A Wolfe,Daniel E Bauer
DOI: https://doi.org/10.1038/s41591-019-0401-y
Abstract:Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by induction of fetal hemoglobin (HbF, α2γ2)1. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adult-stage erythroid cells but are dispensable in non-erythroid cells2-6. CRISPR-Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal γ-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with β-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction.